Abstract
Pleiotrophin (PTN) is an 18 kDa growth factor that has high affinity for heparin and together with midkine form a family of structurally related heparin binding growth factors. Screening of various human tumour cell lines and tumour specimens of different origin revealed that PTN is expressed in many types of cancer, such as gliomas, melanomas, meningiomas, neuroblastomas, choriocarcinomas, leukemias and cancers of pancreas, prostate, stomach, colon, breast, ovaries and lungs. Concerning the biological activity of PTN in cancer, there is ample evidence that it is a tumour-promoting factor, while it has also been suggested that it may be implicated in cellular quiescence rather than an oncogenic phenotype. Besides a direct effect of PTN on tumour cells, there is also a plethora of reports indicating a positive correlation between PTN and in vivo or in vitro angiogenesis, a key step in the progress of many tumours. The identification of PTN domains responsible for its angiogenic and transforming activities is considered important, and data existing so far suggest distinct or even opposite effects for different PTN regions. This review summarises papers and patents dealing with the present understanding of PTN biochemistry, actions, mechanism(s) of action and implication in several diseases, with a special emphasis on its role in diverse tumour types.
Keywords: angiogenesis, cancer, growth factors, heparin affin regulatory peptide, pleiotrophin
Recent Patents on Anti-Cancer Drug Discovery
Title: Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer
Volume: 2 Issue: 2
Author(s): Constantinos Mikelis, Marina Koutsioumpa and Evangelia Papadimitriou
Affiliation:
Keywords: angiogenesis, cancer, growth factors, heparin affin regulatory peptide, pleiotrophin
Abstract: Pleiotrophin (PTN) is an 18 kDa growth factor that has high affinity for heparin and together with midkine form a family of structurally related heparin binding growth factors. Screening of various human tumour cell lines and tumour specimens of different origin revealed that PTN is expressed in many types of cancer, such as gliomas, melanomas, meningiomas, neuroblastomas, choriocarcinomas, leukemias and cancers of pancreas, prostate, stomach, colon, breast, ovaries and lungs. Concerning the biological activity of PTN in cancer, there is ample evidence that it is a tumour-promoting factor, while it has also been suggested that it may be implicated in cellular quiescence rather than an oncogenic phenotype. Besides a direct effect of PTN on tumour cells, there is also a plethora of reports indicating a positive correlation between PTN and in vivo or in vitro angiogenesis, a key step in the progress of many tumours. The identification of PTN domains responsible for its angiogenic and transforming activities is considered important, and data existing so far suggest distinct or even opposite effects for different PTN regions. This review summarises papers and patents dealing with the present understanding of PTN biochemistry, actions, mechanism(s) of action and implication in several diseases, with a special emphasis on its role in diverse tumour types.
Export Options
About this article
Cite this article as:
Constantinos Mikelis , Marina Koutsioumpa and Evangelia Papadimitriou , Pleiotrophin as a Possible New Target for Angiogenesis-Related Diseases and Cancer, Recent Patents on Anti-Cancer Drug Discovery 2007; 2 (2) . https://dx.doi.org/10.2174/157489207780832405
DOI https://dx.doi.org/10.2174/157489207780832405 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
Call for Papers in Thematic Issues
Novel anti-cancer drugs in photoimmunotherapy management: from bench to translational research
In recent years, traditional cancer treatments, such as surgery, chemotherapy, and radiation treatment, etc., may damage the pathological tissue and normal cells. The ideal tumor treatment should be noninvasive, eliminating the primary tumor, making the body produce systemic tumor-specific immunity, eliminating metastases, and having less /no side effects. Recent Patents ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Syncytin and GCMa: Key Regulators in Human Placental Physiology and in Pre-Eclampsia
Current Women`s Health Reviews The Contribution of Nitric Oxide and Carbon Monoxide to Neuronal Function and Development
Central Nervous System Agents in Medicinal Chemistry Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry New Prognostic Markers and Potential Therapeutic Targets in Human Testicular Germ Cell Tumors
Current Medicinal Chemistry Recent Progress in Medicinal Investigations on Trichosanthin and other Ribosome Inactivating Proteins from the Plant Genus Trichosanthes
Current Medicinal Chemistry Dysregulation of LncRNAs in Placenta and Pathogenesis of Preeclampsia
Current Drug Targets Effects of Limonoid Cedrelone on MDA-MB-231 Breast Tumor Cells in vitro
Anti-Cancer Agents in Medicinal Chemistry Iron Oxide Nanoparticles: An Insight into their Biomedical Applications
Current Medicinal Chemistry Modulation of Expression and Activity of ABC Transporters by the Phytoestrogen Genistein. Impact on Drug Disposition
Current Medicinal Chemistry Application of MALDI/SELDI Mass Spectrometry to Cancer Biomarker Discovery and Validation
Current Proteomics Cubilin, the Intrinsic Factor-Vitamin B12 Receptor in Development and Disease
Current Medicinal Chemistry Genetic Alterations in Differentiated Thyroid Cancers
Endocrine, Metabolic & Immune Disorders - Drug Targets Role of Imaging in Testicular Cancer
Current Medical Imaging Prostaglandin J2 Family and the Cardiovascular System
Current Vascular Pharmacology Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Serotonin as a Modulator of Immune Function: An Overview
Current Immunology Reviews (Discontinued) Factors Regulating Human Extravillous Trophoblast Invasion: Chemokine-peptidase and CD9-integrin Systems
Current Pharmaceutical Biotechnology Targeting Nodal and Cripto-1: Perspectives Inside Dual Potential Theranostic Cancer Biomarkers
Current Medicinal Chemistry Antiproliferative Efficacy of Angiotensin II Receptor Blockers in Prostate Cancer
Current Cancer Drug Targets Natural Products Based Anticancer Agents
Mini-Reviews in Organic Chemistry